

ABR 16-Month NM Pathway – Problem Set 6: Radiotherapies

1. What is an authorized user?
2. What is a written directive and what information is required on it?
3. What is the standard dose for Pluvicto? Lutathera? Xofigo?
4. What are the standard # of doses (cycles) and frequency for Pluvicto? Lutathera?
5. A patient experiences toxicity to his first cycle of Pluvicto. His oncologist decides to reduce the subsequent dose. By how much is the dose typically reduced?
6. What are the clinical indications for therapy with ^{177}Lu vipivotide tetraxetan?
7. What defines PSMA positive disease on a PET scan?
8. What did the VISION trial show?

9. Which radiotherapy is associated with carcinoid crisis? What is it and how is it managed?
10. Which amino acids are administered during Lutathera? For what purpose? How long is the AA infusion?
11. When should short and long-acting somatostatin be held for a patient receiving ^{177}Lu -dotatate?
12. What is the half-life of ^{177}Lu ? What are the energies of its 2 most abundant gamma photons?
13. What dose would you recommend for a patient with papillary thyroid cancer and nodal metastases? Pulmonary metastases?
14. What is the equation you would use to determine the ^{131}I dose for a patient with hyperthyroidism in the setting of a Graves? What dose would you choose in the setting of toxic multinodular goiter?

15. Under what circumstances would a radioactive iodine therapy patient necessitate hospital admission? Be sure to list specific numerical parameters.